Abstract
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Universal MMR/MSI testing is standard of care for all patients with newly diagnosed CRC based on multi-society guidelines in the United States. Such testing is intended to identify patients with Lynch Syndrome due to a germline mutation in an MMR gene, but also detects those with sporadic dMMR/MSI-high CRCs. The prognostic utility of MMR/MSI status in non-metastatic colorectal cancer has been studied extensively, yet more limited data are available for its predictive utility. Results have not been entirely consistent due to potential stage-related differences and limited numbers of dMMR/MSI-H patients included in the studies. In this review, we summarize the current evidence for the prognostic and predictive value of dMMR/MSI-H in non-metastatic CRC, and discuss the use of this biomarker for patient management and treatment decisions in clinical practice.
| Original language | English (US) |
|---|---|
| Article number | 300 |
| Pages (from-to) | 1-16 |
| Number of pages | 16 |
| Journal | Cancers |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 2 2021 |
Keywords
- Microsatellite instability
- Mismatch repair deficiency
- Non-metastatic colorectal cancer
- Predictive
- Prognostic
ASJC Scopus subject areas
- Oncology
- Cancer Research